Ferring Pharmaceuticals announces that nadofaragene firadenovec-vncg (ADSTILADRIN ®) has been upgraded to a National Comprehensive Cancer Network® (NCCN®) Category 2A recommended option for the ...

Relmada Therapeutics (NASDAQ:RLMD) outlined progress on its lead urology oncology program and reviewed fourth-quarter results during its fourth quarter and full year 2025 earnings call, highlighting ...

Quarterly Adjusted EBITDA -- $4.9 million, a $6.3 million improvement from negative $1.4 million in the prior year, with a ...

While her surgical oncologist only required the removal of the affected tissue, McFadden-Sabari made a definitive choice for her long-term peace of mind. She opted for a bilateral mastectomy without ...

Dr Anjali Pathak describes ten frequent requests received by her advice and guidance service and explains how they should be managed ...

Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any ...

Hickey, now aged 55, underwent a third mammogram, an ultrasound and a biopsy and was shocked to be diagnosed with ductal carcinoma in situ, an early form of breast cancer.

Chief Executive Officer — Dr. Sergio Traversa Chief Medical Officer, Oncology — Dr. Raj S. Pruthi Chief Financial Officer — Maged S. Shenouda With me on today's call are Relmada Therapeutics, Inc.'s ...

Welcome to the Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now ...

Colon cancer is one of the most common cancers in the U.S., with more than 100,000 cases diagnosed each year. But some people ...